XML 46 R37.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)
12 Months Ended
Aug. 05, 2019
USD ($)
Aug. 05, 2019
EUR (€)
Jun. 06, 2019
EUR (€)
Aug. 06, 2018
USD ($)
$ / shares
shares
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Aug. 31, 2019
USD ($)
Jan. 02, 2019
USD ($)
Product Information [Line Items]                  
Federal insurance limits         $ 250,000        
Number of issued patents domestic.         29        
Number of issued patents foreign         30        
Stock Issued During Period, Value, New Issues         $ 77,031,258 $ 89,907,797 $ 68,572,635    
Number of operating segments         1        
Advertising costs         $ 9,045,571 1,682,746 $ 448,288    
Right of use asset         10,109,154   $ 7,400,000  
Lease liability         $ 10,646,588     $ 7,200,000  
Accounting Standards Update 2016-02 [Member]                  
Product Information [Line Items]                  
Right of use asset                 $ 3,800,000
Lease liability                 $ 4,100,000
License Agreement Theramex                  
Product Information [Line Items]                  
Cash upfront payment received $ 15,506,400 € 14,000,000              
Subscription Agreement Knight [Member]                  
Product Information [Line Items]                  
Stock Issued During Period, Shares, New Issues | shares       3,921,568          
Sale of Stock, Price Per Share | $ / shares       $ 5.10          
Stock Issued During Period, Value, New Issues       $ 20,000,000          
Vitamins and IMVEXXY [Member]                  
Product Information [Line Items]                  
Shelf life of prescription products following product expiration         24 months        
BIJUVA and ANNOVERA [Member]                  
Product Information [Line Items]                  
Shelf life of prescription products following product expiration         18 months        
BIJUVA and ANNOVERA [Member] | License Agreement Theramex                  
Product Information [Line Items]                  
Quarterly royalty payments percentage     5.00%            
Minimum [Member]                  
Product Information [Line Items]                  
Return period of unsalable prescription products         6 months        
Minimum [Member] | License Agreement Theramex                  
Product Information [Line Items]                  
Sales milestone | €     € 25,000,000            
Maximum [Member]                  
Product Information [Line Items]                  
Return period of unsalable prescription products         12 months        
Maximum [Member] | License Agreement Theramex                  
Product Information [Line Items]                  
Regulatory milestone payments | €     2,000,000            
Sales milestone payment | €     27,500,000            
Sales milestone | €     € 100,000,000            
Land and Building [Member] | Minimum [Member]                  
Product Information [Line Items]                  
Useful life of assets         3 years        
Land and Building [Member] | Maximum [Member]                  
Product Information [Line Items]                  
Useful life of assets         7 years        
Software and Software Development Costs [Member] | Minimum [Member]                  
Product Information [Line Items]                  
Useful life of assets         5 years        
Software and Software Development Costs [Member] | Maximum [Member]                  
Product Information [Line Items]                  
Useful life of assets         7 years        
Accounts Receivable [Member] | Customer A [Member]                  
Product Information [Line Items]                  
Concentration risk         36.00% 42.00%      
Accounts Receivable [Member] | Customer B [Member]                  
Product Information [Line Items]                  
Concentration risk         21.00% 24.00%      
Accounts Receivable [Member] | Customer C [Member]                  
Product Information [Line Items]                  
Concentration risk         16.00% 13.00%      
Accounts Receivable [Member] | Customer D [Member]                  
Product Information [Line Items]                  
Concentration risk         11.00%